Navamedic (NAVA) M&A Announcement summary

Deal rationale and strategic fit

• Expands presence into addiction treatment, a fast-growing therapeutic area with significant societal impact.

• Acquired products align with mission to deliver high-quality, specialized treatments to hospitals and pharmacies.

• Supports ambition to become a leading Nordic provider and broadens proprietary product range.

• Seamless integration enables rapid market access and geographic expansion across Nordics and select European markets.

• Strong fit with existing operations in terms of footprint, logistics, and tender management.

Financial terms and conditions

• Total consideration up to NOK 225 million: NOK 185 million at closing, NOK 40 million in two tranches based on sales milestones.

• Funded by NOK 110 million in new debt and a NOK 110–130 million rights issue, underwritten by largest shareholder.

• Rights issue subscription price set at NOK 21.50 per share, with minimum proceeds underwritten by the largest shareholder.

• NOK 5 million break fee payable if deal is terminated due to lack of rights issue approval.

• Completion conditional on EGM approval, expected by July 15, 2025.

Synergies and expected cost savings

• Integration into existing commercial platform expected to deliver significant synergies in logistics, warehousing, and tender management.

• Anticipated annual EBITDA contribution of approximately NOK 25 million based on 2024 net sales, with potential for further growth.